HRP20241052T1 - Semaglutid, namijenjen liječenju alzheimerove demencije - Google Patents
Semaglutid, namijenjen liječenju alzheimerove demencije Download PDFInfo
- Publication number
- HRP20241052T1 HRP20241052T1 HRP20241052TT HRP20241052T HRP20241052T1 HR P20241052 T1 HRP20241052 T1 HR P20241052T1 HR P20241052T T HRP20241052T T HR P20241052TT HR P20241052 T HRP20241052 T HR P20241052T HR P20241052 T1 HRP20241052 T1 HR P20241052T1
- Authority
- HR
- Croatia
- Prior art keywords
- glp
- receptor agonist
- semaglutide
- intended
- accordance
- Prior art date
Links
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 title claims 19
- 229950011186 semaglutide Drugs 0.000 title claims 19
- 108010060325 semaglutide Proteins 0.000 title claims 19
- 208000024827 Alzheimer disease Diseases 0.000 title claims 4
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 claims 28
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 28
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 claims 1
- 208000015756 familial Alzheimer disease Diseases 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical class CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- UOENJXXSKABLJL-UHFFFAOYSA-M sodium;8-[(2-hydroxybenzoyl)amino]octanoate Chemical compound [Na+].OC1=CC=CC=C1C(=O)NCCCCCCCC([O-])=O UOENJXXSKABLJL-UHFFFAOYSA-M 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19207501 | 2019-11-06 | ||
| EP20186623 | 2020-07-20 | ||
| EP20803489.2A EP4054620B1 (en) | 2019-11-06 | 2020-11-05 | Semaglutide in the treatment of alzheimer's dementia |
| PCT/EP2020/081087 WO2021089678A1 (en) | 2019-11-06 | 2020-11-05 | Glp-1 receptor agonists in dementia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20241052T1 true HRP20241052T1 (hr) | 2024-11-08 |
Family
ID=73172681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20241052TT HRP20241052T1 (hr) | 2019-11-06 | 2020-11-05 | Semaglutid, namijenjen liječenju alzheimerove demencije |
Country Status (19)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3154744A1 (en) | 2019-11-06 | 2021-05-14 | Sarah FRIEDRICH | Glp-1 receptor agonists in dementia |
| US20230088005A1 (en) * | 2020-01-30 | 2023-03-23 | Eli Lilly And Company | Therapeutic uses of dulaglutide |
| EP4262873A4 (en) * | 2020-12-16 | 2024-12-11 | The Chinese University of Hong Kong | A method for reversing aging brain functional decline |
| CN118510545A (zh) | 2021-12-02 | 2024-08-16 | 哥本哈根大学 | 用于治疗神经退行性疾病的肽-药物缀合物 |
| CN120731085A (zh) * | 2023-03-02 | 2025-09-30 | 甘李药业股份有限公司 | 一种glp-1化合物的医药用途 |
| WO2026096637A1 (en) * | 2024-10-30 | 2026-05-07 | Tiziana Life Sciences Plc | Glp-1 agonists and foralumab combination therapies |
| CN120131965A (zh) * | 2025-04-10 | 2025-06-13 | 瓯江实验室 | Glp-1受体激动剂治疗阿尔茨海默病的用途 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| AU3357800A (en) | 1999-02-05 | 2000-08-25 | Emisphere Technologies, Inc. | Method of preparing alkylated salicylamides |
| AU2001275231A1 (en) | 2000-06-02 | 2001-12-11 | Emisphere Technologies, Inc. | Method of preparing salicylamides |
| EP1411968B1 (en) | 2001-07-31 | 2008-09-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Glp-1 exendin-4 peptide analogs and uses thereof |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| MX2008001468A (es) | 2005-06-30 | 2008-04-07 | Sod Conseils Rech Applic | Composiciones farmaceuticas del peptido similar al glucagon-1. |
| WO2007121318A2 (en) | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
| EP2066337A2 (en) | 2006-08-04 | 2009-06-10 | Amylin Pharmaceuticals, Inc. | Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen |
| MX2009002121A (es) | 2006-09-07 | 2009-05-20 | Hoffmann La Roche | Proceso para la manufactura del acido n-(8-[2-hidroxibenzoil]-amin o)caprilico. |
| US8756102B2 (en) * | 2009-11-06 | 2014-06-17 | Edatanetworks Inc. | Method, system, and computer program for attracting local and regional businesses to an automated cause marketing environment |
| US20120329711A1 (en) | 2009-12-16 | 2012-12-27 | Nordisk A/S | Glp-1 receptor agonist compounds with a modified n-terminus |
| WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| MX377589B (es) | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| AU2012241894B2 (en) | 2011-04-12 | 2015-12-03 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
| WO2013004983A1 (en) | 2011-07-04 | 2013-01-10 | Imperial Innovations Limited | Novel compounds and their effects on feeding behaviour |
| HUE049152T2 (hu) * | 2012-07-01 | 2020-09-28 | Novo Nordisk As | Hosszantartó hatású GLP-1 peptidek alkalmazása |
| WO2015155151A1 (en) | 2014-04-07 | 2015-10-15 | Novo Nordisk A/S | Double-acylated glp-1 compounds |
| WO2016198624A1 (en) * | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| US20170112897A1 (en) * | 2015-10-23 | 2017-04-27 | Cedars-Sinai Medical Center | Methods for treating brain insulin resistance |
| AU2016379403B2 (en) * | 2015-12-23 | 2020-03-12 | The Johns Hopkins University | Long-acting GLP-1r agonist as a therapy of neurological and neurodegenerative conditions |
| US20190142905A1 (en) | 2016-04-19 | 2019-05-16 | Ureka Sarl | Peptide-oligourea foldamer compounds and methods of their use |
| GB201620611D0 (en) | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
| CA3154744A1 (en) | 2019-11-06 | 2021-05-14 | Sarah FRIEDRICH | Glp-1 receptor agonists in dementia |
| IL294521A (en) | 2020-02-18 | 2022-09-01 | Novo Nordisk As | glp-1 compounds and their uses |
-
2020
- 2020-11-05 CA CA3154744A patent/CA3154744A1/en active Pending
- 2020-11-05 AU AU2020377469A patent/AU2020377469A1/en active Pending
- 2020-11-05 HU HUE20803489A patent/HUE067514T2/hu unknown
- 2020-11-05 MA MA57599A patent/MA57599B1/fr unknown
- 2020-11-05 KR KR1020227015440A patent/KR20220110731A/ko active Pending
- 2020-11-05 PH PH1/2022/550842A patent/PH12022550842A1/en unknown
- 2020-11-05 RS RS20240863A patent/RS65780B1/sr unknown
- 2020-11-05 EP EP20803489.2A patent/EP4054620B1/en active Active
- 2020-11-05 BR BR112022007721A patent/BR112022007721A2/pt unknown
- 2020-11-05 ES ES20803489T patent/ES2984177T3/es active Active
- 2020-11-05 PL PL20803489.2T patent/PL4054620T3/pl unknown
- 2020-11-05 IL IL291876A patent/IL291876A/en unknown
- 2020-11-05 HR HRP20241052TT patent/HRP20241052T1/hr unknown
- 2020-11-05 JP JP2022521146A patent/JP7670698B2/ja active Active
- 2020-11-05 MX MX2022004779A patent/MX2022004779A/es unknown
- 2020-11-05 EP EP24175772.3A patent/EP4414031A3/en active Pending
- 2020-11-05 WO PCT/EP2020/081087 patent/WO2021089678A1/en not_active Ceased
- 2020-11-05 CN CN202080076976.0A patent/CN114728042A/zh active Pending
- 2020-11-06 TW TW109138851A patent/TWI890704B/zh active
- 2020-11-06 TW TW114103408A patent/TWI923289B/zh active
-
2022
- 2022-05-04 US US17/736,116 patent/US20220280612A1/en not_active Abandoned
-
2023
- 2023-06-12 US US18/208,485 patent/US20230302094A1/en not_active Abandoned
-
2024
- 2024-01-30 US US18/426,412 patent/US20240207364A1/en active Pending
- 2024-12-04 JP JP2024211204A patent/JP2025027130A/ja active Pending
- 2024-12-12 US US18/979,068 patent/US12539326B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RS65780B1 (sr) | 2024-08-30 |
| WO2021089678A1 (en) | 2021-05-14 |
| EP4054620A1 (en) | 2022-09-14 |
| EP4414031A3 (en) | 2025-02-05 |
| TW202519256A (zh) | 2025-05-16 |
| ES2984177T3 (es) | 2024-10-29 |
| MA57599B1 (fr) | 2024-06-28 |
| MX2022004779A (es) | 2022-06-14 |
| TWI923289B (zh) | 2026-04-21 |
| JP2023500032A (ja) | 2023-01-04 |
| IL291876A (en) | 2022-06-01 |
| EP4054620C0 (en) | 2024-05-29 |
| BR112022007721A2 (pt) | 2022-07-12 |
| KR20220110731A (ko) | 2022-08-09 |
| PL4054620T3 (pl) | 2024-10-14 |
| CA3154744A1 (en) | 2021-05-14 |
| EP4414031A2 (en) | 2024-08-14 |
| TW202118509A (zh) | 2021-05-16 |
| US20220280612A1 (en) | 2022-09-08 |
| EP4054620B1 (en) | 2024-05-29 |
| US12539326B2 (en) | 2026-02-03 |
| US20240207364A1 (en) | 2024-06-27 |
| TWI890704B (zh) | 2025-07-21 |
| US20250099549A1 (en) | 2025-03-27 |
| JP7670698B2 (ja) | 2025-04-30 |
| PH12022550842A1 (en) | 2023-10-09 |
| CN114728042A (zh) | 2022-07-08 |
| US20230302094A1 (en) | 2023-09-28 |
| AU2020377469A1 (en) | 2022-04-28 |
| HUE067514T2 (hu) | 2024-10-28 |
| JP2025027130A (ja) | 2025-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023500032A5 (cg-RX-API-DMAC7.html) | ||
| HRP20230272T1 (hr) | Postupci za liječenje cistične fibroze | |
| HRP20251112T1 (hr) | Čvrsti pripravci koji sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline | |
| RU2729066C2 (ru) | Диацереин или его аналоги для ингибирования экспрессии asc, экспрессии nlrp3 и/или образования комплекса nlrp3 инфламмасом | |
| HRP20251261T1 (hr) | Inhibitori csf1r za uporabu u liječenju tenosinovijalnih gigantocelularnih tumora | |
| HRP20221263T1 (hr) | Ciklički di-nukleotidni spojevi i postupci uporabe | |
| HRP20231613T1 (hr) | Pripravci koji sadrže sredstvo za unošenje i njihova priprava | |
| CN105209036B (zh) | 氧杂双环庚烷和氧杂双环庚烯的配制品 | |
| DK1256343T3 (da) | Flibanserin til behandlingen af extrapyramidale bevægelseslidelser | |
| BR112017026417B1 (pt) | Formulação para o tratamento de distúrbios da boca, garganta e vias respiratórias | |
| IL265761B1 (en) | Oral terlipressin compositions for use in treatment of ascites | |
| MX2024008330A (es) | Combinacion de obicetrapib e inhibidor de sglt2 | |
| RU2013150659A (ru) | Пероральное введение кальцитонина | |
| US20110166234A1 (en) | Medicinal product and treatment | |
| IL272834B2 (en) | Amantadine compositions, preparations thereof, and methods of use | |
| RU2005105691A (ru) | Пероральное введение кальцитонина | |
| HRP20211661T1 (hr) | Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti | |
| WO2007038428A3 (en) | Prevention and treatment of gastrointestinal and bladder disorders using active vitamin d compounds | |
| JP2021506907A5 (cg-RX-API-DMAC7.html) | ||
| JP2019535830A5 (cg-RX-API-DMAC7.html) | ||
| US11458160B2 (en) | Food supplements for use in the prophylaxis and treatment of migraine | |
| ES2424417B1 (es) | Combinación de un aine y un aminoacido | |
| BR112020017773A2 (pt) | Composição farmacêutica compreendendo polmacoxibe e pregabalina para tratamento de dor | |
| HRP20230677T1 (hr) | Kombinacija ibuprofena i tramadola za ublažavanje boli | |
| KR20210021356A (ko) | 항-n-메틸-d-아스파르테이트 수용체(anti-n-methyl-d-aspartate receptor) 뇌염 예방 또는 치료에 사용하기 위한 벤조산 또는 이의 염 및 유도체 |